Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review,        editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name
E-mail
Phone
Title
Content
Verification Code
x Close Forever Close
Volume 25 Issue 6
. 
Turn off MathJax
Article Contents
Article Navigation >  Journal of Pharmaceutical Practice and Service  > 2007  >  (6): 399-400

JIA Guo-qiang, YANG Ya-qing. Clinical curative effect analysis of gefitinib for treat NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2007, (6): 399-400.
Citation: JIA Guo-qiang, YANG Ya-qing. Clinical curative effect analysis of gefitinib for treat NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2007, (6): 399-400.
shu

Clinical curative effect analysis of gefitinib for treat NSCLC

  • Department Pharmacy,General Hospital of PLA,Beijing 100853,China

  • Received Date: 2007-09-05
  • Objective :To analyze clinical curative effect of Gefitinib to treat NSCLC(non-small cell lung cancer). Methods :40 cases in-patient with NSCLC in Hospital of PLA General Hospital during Juan 2005 to Dec 2006,were administrated Gefitinib 250 mg daily orally,and investigated for it's curative effect. Results :The total effective rate was 35.0%,CR(complete remission)1 case,PR(partial remission) 13 cases,the disease control rate was 82.5%(CR was 1 case,PR was 13 cases,basio-stabilization was 19 cases).There were 29 male patients and 11 females,and effective rate were 55.2% and 36.4% respectively(P<0.05).The main adverse reaction were nausea and vomiting(37%),anorexy(25%),and exanthem(18%). Conclusion : Gefitinib has a better curative effect to treat NSCLC,and the adverse effect is gently,it can improve majority patient quality of life and survival.
  • 加载中
通讯作者: 陈斌, [email protected]
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Get Citation
PDF
XML

Article Metrics

Article views(2374) PDF downloads(38) Cited by()

Related
Proportional views

Clinical curative effect analysis of gefitinib for treat NSCLC

  • Department Pharmacy,General Hospital of PLA,Beijing 100853,China
  • Received Date: 2007-09-05

Abstract: Objective :To analyze clinical curative effect of Gefitinib to treat NSCLC(non-small cell lung cancer). Methods :40 cases in-patient with NSCLC in Hospital of PLA General Hospital during Juan 2005 to Dec 2006,were administrated Gefitinib 250 mg daily orally,and investigated for it's curative effect. Results :The total effective rate was 35.0%,CR(complete remission)1 case,PR(partial remission) 13 cases,the disease control rate was 82.5%(CR was 1 case,PR was 13 cases,basio-stabilization was 19 cases).There were 29 male patients and 11 females,and effective rate were 55.2% and 36.4% respectively(P<0.05).The main adverse reaction were nausea and vomiting(37%),anorexy(25%),and exanthem(18%). Conclusion : Gefitinib has a better curative effect to treat NSCLC,and the adverse effect is gently,it can improve majority patient quality of life and survival.

JIA Guo-qiang, YANG Ya-qing. Clinical curative effect analysis of gefitinib for treat NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2007, (6): 399-400.
Citation: JIA Guo-qiang, YANG Ya-qing. Clinical curative effect analysis of gefitinib for treat NSCLC[J]. Journal of Pharmaceutical Practice and Service, 2007, (6): 399-400.
shu

    HTML

Catalog

    版权所有：《药学实践与服务》编辑委员会

    Supervisor & Sponsors: Address: No 325 Guohe Road, ShanghaiPost Code: 200433

    Tel: （021）81871324,81871397 E-mail: [email protected]

    网站备案号 沪ICP备05003363号-1

    Supported by: Beijing Renhe Information Technology Co., Ltd.  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return